Related Experiment Video
Updated: Jun 12, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the
A G Semb1, T K Kvien, A H Aastveit
1Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. a-semb@diakonsyk.no
Insights
Patients with rheumatoid arthritis (RA) have a 1.6 times higher risk of acute myocardial infarction (AMI) and ischaemic stroke (IS). Cholesterol and triglycerides predict cardiovascular events in the general population but not consistently in RA patients.
Area of Science:
- Cardiovascular epidemiology
- Rheumatology
- Lipid metabolism
Background:
- Rheumatoid arthritis (RA) is associated with increased cardiovascular disease (CVD) risk.
- The predictive value of lipid profiles for CVD events in RA patients remains incompletely understood.
Purpose of the Study:
- To investigate the incidence of acute myocardial infarction (AMI) and ischaemic stroke (IS) in individuals with and without RA.
- To assess the predictive capacity of total cholesterol (TC) and triglycerides (TG) for AMI and IS in both RA patients and controls.
Main Methods:
- The Apolipoprotein MOrtality RISk (AMORIS) Study cohort of 480,406 individuals, including 1,779 with RA, was followed for a median of 11.8 years.
- Cox regression analysis was employed to calculate hazard ratios (HR) per standard deviation (SD) increase in TC or TG, adjusted for age, diabetes, and hypertension.
Main Results:
- Individuals with RA exhibited significantly lower TC and TG levels compared to those without RA.
- Despite lower lipid levels, RA patients had a 1.6-fold higher rate of AMI and IS.
- TC was a significant predictor of IS in RA patients (HR/SD 1.20, p=0.02) and nearly significant for AMI (HR/SD 1.13, p=0.07).
- TG showed a weak association with IS (HR/SD 1.13, p=0.06) but not AMI.
- In contrast, both TC and TG were significant predictors of AMI and IS in individuals without RA.
Conclusions:
- Patients with RA experience a substantially higher incidence of AMI and IS compared to the general population.
- While TC and TG are established predictors of cardiovascular events in non-RA individuals, their predictive utility in RA patients is inconsistent.
- Further research is warranted to elucidate the specific mechanisms driving cardiovascular risk in RA.
Objectives:
To examine the rates of acute myocardial infarction (AMI) and ischaemic stroke (IS) and to examine the predictive value of total cholesterol (TC) and triglycerides (TG) for AMI and IS in patients with rheumatoid arthritis (RA) and people without RA.
Methods:
In the Apolipoprotein MOrtality RISk (AMORIS) Study 480 406 people (including 1779 with RA, of whom 214 had an AMI and 165 an IS) were followed for 11.8 (range 7-17) years. Cox regression analysis was used to calculate HR per SD increase in TC or TG with 95% CI. All values were adjusted for age, diabetes and hypertension.
Results:
The levels of TC and TG were significantly lower in patients with RA than in people without RA. Despite this, the rate of AMI and IS per 1000 years was at least 1.6 times higher in RA than non-RA. TC was nearly significantly predictive for AMI (HR/SD 1.13 (95% CI 0.99 to 1.29), p=0.07) and significantly predictive for future IS in RA (HR/SD 1.20 (95% CI 1.03 to 1.40), p=0.02). TG had no relationship to development of AMI (1.07, 0.94 to 1.21, p=0.29), but was weakly related to IS (1.13, 0.99 to 1.27, p=0.06). In contrast, both TC and TG were significant predictors of AMI and IS in people without RA.
Conclusions:
Patients with RA had 1.6 times higher rate of AMI and IS than people without RA. TC and TG were significant predictors of AMI and IS in people without RA, whereas the predictive value in RA was not consistent.
Related Concept Videos
Atherosclerosis III: Management
Rheumatic Heart Disease I: Introduction
Atherosclerosis I: Introduction
Inflammation
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Rheumatic Heart Disease III: Medical Management